MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.5900 -0.0300 (-4.84%)
Streaming Delayed Price Updated: 3:15 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 124,900
Open 0.6300
Bid (Size) 0.5600 (5,000)
Ask (Size) 0.6300 (500)
Prev. Close 0.6200
Today's Range 0.5300 - 0.6500
52wk Range 0.3200 - 1.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
Via ACCESS Newswire
News headline image
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
Via ACCESS Newswire

Performance

YTD
-9.2%
-9.2%
1 Month
-9.2%
-9.2%
3 Month
-31.4%
-31.4%
6 Month
+9.3%
+9.3%
1 Year
+43.9%
+43.9%

More News

Read More
News headline image
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
Via ACCESS Newswire
News headline image
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
Via ACCESS Newswire
News headline image
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Via ACCESS Newswire
News headline image
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
Via ACCESS Newswire
News headline image
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
Via ACCESS Newswire
News headline image
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
Via ACCESS Newswire
News headline image
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
Via ACCESS Newswire
News headline image
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
Via ACCESS Newswire
News headline image
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
Via ACCESS Newswire
News headline image
BioNxt Solutions Completes Up-Listing to The OTCQB Market
Via ACCESS Newswire
News headline image
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
Via ACCESS Newswire
News headline image
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
Via ACCESS Newswire
News headline image
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
Via ACCESS Newswire
News headline image
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
Via ACCESS Newswire
News headline image
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
Via ACCESS Newswire
News headline image
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
Via ACCESS Newswire
News headline image
BioNxt Solutions Provides Bi-weekly MCTO Status Report
Via ACCESS Newswire

Frequently Asked Questions

Is BNXT publicly traded?
Yes, BNXT is publicly traded.
What exchange does BNXT trade on?
BNXT trades on the Canadian Securities Exchange
What is the ticker symbol for BNXT?
The ticker symbol for BNXT is BNXT on the Canadian Securities Exchange
What is the current price of BNXT?
The current price of BNXT is 0.5900
When was BNXT last traded?
The last trade of BNXT was at 01/09/26 03:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story